Literature DB >> 26873057

A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice.

Rui Zhu1, Jian Liu2, Chunye Chen1, Xiangzhong Ye3, Longfa Xu1, Wei Wang2, Qinjian Zhao1, Hua Zhu4, Tong Cheng5, Ningshao Xia6.   

Abstract

Varicella-zoster virus (VZV) is a highly infectious agent of varicella and herpes zoster (HZ). Vaccination is by far the most effective way to prevent these diseases. More safe, stable and efficient vaccines, such as epitope-based vaccines, now have been increasingly investigated by many researchers. However, only a few VZV neutralizing epitopes have been identified to date. We have previously identified a linear epitope between amino acid residues 121 and 135 of gE. In this study, we validated that this epitope is highly conserved amongst different VZV strains that covered five existing phylogenetic clades with an identity of 100%. We evaluated the immunogenicity of the recombinant hepatitis B virus core (HBc) virus-like particles (VLPs) which included amino acids (121-135). VZV-gE-specific antibodies were detected in immunized mouse serum using ELISA. The anti-peptide antiserum positively detected VZV via Western blot and immunofluorescent staining assays. More importantly, these peptides could neutralize VZV, indicating that these peptides represented neutralizing epitopes. These findings have important implications for the development of epitope-based protective VZV vaccines.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epitope vaccine; Glycoprotein E; Neutralizing linear epitope; Varicella-zoster virus

Mesh:

Substances:

Year:  2016        PMID: 26873057     DOI: 10.1016/j.vaccine.2016.02.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine.

Authors:  Ning Luan; Han Cao; Yunfei Wang; Kangyang Lin; Cunbao Liu
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

2.  Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice.

Authors:  Yunfei Wang; Jialong Qi; Han Cao; Cunbao Liu
Journal:  Virol Sin       Date:  2020-08-05       Impact factor: 4.327

Review 3.  A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection.

Authors:  Cody S Nelson; Betsy C Herold; Sallie R Permar
Journal:  NPJ Vaccines       Date:  2018-09-20       Impact factor: 9.399

4.  A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.

Authors:  Xiao Zhang; Bingchun Zhao; Mingmei Ding; Shuo Song; Yinfeng Kang; Yang Yu; Miao Xu; Tong Xiang; Ling Gao; Qisheng Feng; Qinjian Zhao; Mu-Sheng Zeng; Claude Krummenacher; Yi-Xin Zeng
Journal:  Theranostics       Date:  2020-04-27       Impact factor: 11.556

5.  Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice.

Authors:  Han Cao; Yunfei Wang; Ning Luan; Cunbao Liu
Journal:  Vaccines (Basel)       Date:  2021-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.